Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

P. Sonneveld; R. Hajek; A. Nagler; A. Spencer; J. Bladé; T. Robak; S.H. Zhuang; J.L. Harousseau; R.Z. Orlowski; H.M. Lokhorst; Study investigators DOXIL-MMY-3001

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Translated title of the contribution: Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

P. Sonneveld, R. Hajek, A. Nagler, A. Spencer, J. Bladé, T. Robak, S.H. Zhuang, J.L. Harousseau, R.Z. Orlowski, H.M. Lokhorst, Study investigators DOXIL-MMY-3001

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Original language	Undefined/Unknown
Pages (from-to)	1529-1537
Number of pages	9
Journal	Cancer
Volume	112
Issue number	7
Publication status	Published - 2008

Cite this

Sonneveld, P., Hajek, R., Nagler, A., Spencer, A., Bladé, J., Robak, T., Zhuang, S. H., Harousseau, J. L., Orlowski, R. Z., Lokhorst, H. M., & DOXIL-MMY-3001, S. I. (2008). Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 112(7), 1529-1537.

@article{96fb400a48d243398997f3dd0299bafc,

title = "Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.",

author = "P. Sonneveld and R. Hajek and A. Nagler and A. Spencer and J. Blad{\'e} and T. Robak and S.H. Zhuang and J.L. Harousseau and R.Z. Orlowski and H.M. Lokhorst and DOXIL-MMY-3001, {Study investigators}",

year = "2008",

language = "Undefined/Unknown",

volume = "112",

pages = "1529--1537",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley & Sons Inc.",

number = "7",

}

Sonneveld, P, Hajek, R, Nagler, A, Spencer, A, Bladé, J, Robak, T, Zhuang, SH, Harousseau, JL, Orlowski, RZ, Lokhorst, HM & DOXIL-MMY-3001, SI 2008, 'Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.', Cancer, vol. 112, no. 7, pp. 1529-1537.

TY - JOUR

T1 - Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

AU - Sonneveld, P.

AU - Hajek, R.

AU - Nagler, A.

AU - Spencer, A.

AU - Bladé, J.

AU - Robak, T.

AU - Zhuang, S.H.

AU - Harousseau, J.L.

AU - Orlowski, R.Z.

AU - Lokhorst, H.M.

AU - DOXIL-MMY-3001, Study investigators

PY - 2008

Y1 - 2008

M3 - Article

SN - 0008-543X

VL - 112

SP - 1529

EP - 1537

JO - Cancer

JF - Cancer

IS - 7

ER -